medi USA Launches New circaid® profile Foam Sleeve for Lymphedema

medi USA announced the launch of the new circaid® profile foam sleeve for lymphedema management at-home. The circaid profile foam sleeve is an alternative or supplement to nighttime and home-care bandaging applications that applies gradient compression to the affected limb or limbs.

Video here.

Engineered with first-use foam for hygenic confidence and brrr® cooling fabric proven to keep patients cooler, the circaid profile allows wearers to manage their own therapy comfortably at home. The foam creates a massaging effect and promotes continuous airflow, and with an anatomic fit, the sleeve provides full limb coverage. Included standard is an energy oversleeve available in four color choices that provides added compression for maximum effect, an EZ-on system that easily applies the sleeve and the profile anchor system to help keep the compressive oversleeve in place.

“The profile showcases medi’s commitment to quality and passion for originality and innovation. From the project start, there was an all hands-on deck approach and shared enthusiasm to breathe new life into a familiar concept,” said Moses Lipshaw, Director of Research & Development at medi USA. “With simplified donning, cooling comfort, long-lasting compression and premium features, patients will benefit from a new standard in padded night care.”

The brrr® Triple Chill Effect included in the circaid profile foam sleeve has three unique cooling effects  – cooling minerals, rapid drying and active wicking – that continually enhance comfort and reduce the temperature of the skin.

The circaid profile foam sleeve offers the widest ready-to-wear size range in the market with 16 sizes and 2 lengths, and it has a 30-day fit guarantee. For easy ordering, the profile uses the same size chart as the mediven® harmony and comfort arm sleeves. Along with the ready-to-wear option, it is also available in custom-made sizing and includes a 1-year the New You! guarantee for a one-time, free reduction alteration to reward patients who succeed in their treatment plan.

The new circaid profile joins a full range of compression products offered by medi in their circaid inelastic compression line, inspired by nature. medi creates compression products that fit every patient for all stages of venous and lymphatic conditions.

Sourcemedi USA

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version